Zoledronic Acid (Za) and Treatment of Bone Metastasis in Patients With Advanced Lung Cancer (Nsclc and Sclc)
Ester Del Signore(Policlinico Umberto I), M. Di Seri(Sapienza University of Rome), Cristina Raimondi(Sapienza University of Rome), Salvatore Minisola(Sapienza University of Rome), Federica Recine(Azienda Ospedaliera San Giovanni Addolorata), Silvia Quadrini(Policlinico Umberto I), Rita De Sanctis(Humanitas University), Paolo Grassi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Sofia Basile(University of Catania), Valeria Fassino, Francesco Longo, Andrea Zivi(Royal Marsden NHS Foundation Trust), Luigi Cerbone(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo)
Unknown
January 1, 2008
Cited by 1
Related Papers
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178